Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rosuvastatin versus placebo study of transthoracic Doppler echocardiography coronary flow reserve in adults with increased cardiovascular risk
2008-002332-15Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Aug 2008
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in cardiac event risk comparing Rosuvastatin with Placebo (2 arms). Primary endpoints: Change in TTDE-CFR peak velocity after 1 month in rosuvastatin group and Usefulness of TTDE to assess CFR as a composite biomarker. Started Aug 2008; status: completed.
02
Drugs
rosuvastatin
03
Conditions
cardiac event risk
Beyond the preview
Go deeper on 2008-002332-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-002332-15.